NCT06686056Completed
Artificial Intelligence-Enhanced Management for Coronary Heart Disease (AIM-CHD) : Impact on Cholesterol and Other CHD Risk Factors
A Single-Center, Open-Label, Randomized, Parallel Controlled Trial Evaluating the Effectiveness of Artificial Intelligence-Enhanced Management for Coronary Heart Disease (AIM-CHD) Delivered Via Mobile Application
Source: ClinicalTrials.gov · Last updated 19 Sept 2025
Brief summary (registry, in English)
The goal of this clinical trial is to find out if an artificial intelligence (AI)-enhanced mobile app can help people with coronary heart disease (CHD) better manage their health after being discharged from the hospital. The main questions it aims to answer are: 1. Does the AI-enhanced app help lower bad cholesterol (LDL-C) levels within 3 months after leaving the hospital? 2. Does the app improve other health measures, like blood pressure, blood sugar control, weight, medication adherence and cardiac events? Researchers will compare the AI-enhanced app to usual care, where participants receive usual health advice without using the app. Participants will: 1. Be randomly assigned to use either the AI-enhanced app or receive usual care. 2. Use the app to track and manage their health, receive reminders, and get educational tips. 3. Attend checkups at 3 months to measure cholesterol levels and other health outcomes. The study hopes to show that using an AI-enhanced app can make it easier for people with CHD to stay healthy and avoid future heart problems.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 1100 (actual)
- First submitted
- 11 Nov 2024
- Start date
- 23 Nov 2024
- Primary completion date
- 30 Jun 2025
- Lead sponsor
- China National Center for Cardiovascular Diseases
- Diseases
- Coronary artery disease
- NCT number
- NCT06686056
What you commit to
- Study type: Interventional
- Participants enrolled: 1100
- From 23 Nov 2024 to the primary completion date, 30 Jun 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- severe cognitive impairment
- advanced malignant tumors
- severe multi-organ failure
Other
- expected survival of less than 3 months
- refusal to sign the informed consent form
Who the study is looking for
- CHD patients aged 18-85 years
- ability of the patient or close relatives to use smartphones and applications
- willingness to participate and sign the informed consent form
Age in the registry: 18 years to 85 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fuwai Hospital, Chinese Academy of Medical Sciences/National Center for Cardiovascular Diseases Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
Related publications
This page is information, not medical advice. Discuss any trial with your doctor.